Hydroxychloroquine, is it worth reducing the dose for safety?

Hydroxychloroquine was first developed for the treatment of malaria, and it was later found to have a certain immunomodulatory effe.

Hydroxychloroquine was first developed for the treatment of malaria, and it was later found to have a certain immunomodulatory effe.

In addition, hydroxychloroquine may even reduce the risk of infection in patients with connective tissue disease in the context of the use of glucocorticoids and other immunosuppressive agen.

 

Nonetheless, a notable side effect of hydroxychloroquine is retinopathy , which can lead to vision loss and even blindness in use.

Nonetheless, a notable side effect of hydroxychloroquine is retinopathy , which can lead to vision loss and even blindness in use.

Therefore, as early as 2011, the American Academy of Ophthalmology issued a recommendation that the recommended dose of hydroxychloroquine should be less than 5mg/kg (ideal body weigh.

It is true that reducing the dosage of hydroxychloroquine will likely reduce the risk of retinopathy in patien.

It is true that reducing the dosage of hydroxychloroquine will likely reduce the risk of retinopathy in patien.

Therefore, a group of rheumatologists from Brazil conducted a study to investigate the effect of hydroxychloroquine at relatively low doses (2-3 mg/kg/day) (2-3 mg/kg/day.

This study included 73 patients with stable lupus nephritis who were prescribed standard American Academy of Ophthalmology hydroxychloroquine recommended doses for ≥6 months and had acceptable baseline hydroxychloroquine plasma concentrations (≥615 ng/mL) (≥615 ng/ m.

The study found:

 (1) The plasma concentration of hydroxychloroquine in the low-dose group decreased significantly in thethird month compared with the baseline period;

 (1) The plasma concentration of hydroxychloroquine in the low-dose group was significantly decreased in the3rd to 3rd month compared with the baseline period;

(2) At the6thand12thmonths, the recurrence rate of the hydroxychloroquine low-dose group was nearlytwicethat of the full-dose gro.

(2) In the6thto 6thmonth and the12th to 12thmonth, the disease recurrence rate of the low-dose hydroxychloroquine group was nearly 2timesthat of the full - dose grou.

In conclusion, low-dose ( 2-3 mg/kg/day ) treatment of hydroxychloroquine is difficult to maintain stable disease in patients with lupus nephrit.

Although it seems that this problem is more serious, but in China, there is no need to worry too mu.

It is only for doctors to learn and communicate, not for diagnosis and treatment
Clinic message here